The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome

Pharmacological Research

Volumn 60, Issue 3, 2009, Pages 195-206

  Huang, Tom Hsun Wei ^a   Teoh, Aik Wei ^a   Lin, Bei Lun ^a   Lin, Diana Shu Hsuan ^a   Roufogalis, Basil ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Farnesoid X receptor; FXR; Herbal; Liver X receptors; LXR; Natural Ligands; Peroxisome proliferator activated receptors; PPAR

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ASTRAGALUS MEMBRANACEUS EXTRACT; CELL NUCLEUS RECEPTOR; CRATAEGUS EXTRACT; CUCURBITACIN GLYCOSIDE; FIBRIC ACID DERIVATIVE; GINGER EXTRACT; GINSENG EXTRACT; GLUCOSE; GYMNEMA SYLVESTRE EXTRACT; GYPENOSIDE; HALOFENATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MELISSA OFFICINALIS EXTRACT; MOMORDICA CHARANTIA EXTRACT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; REHMANNIA EXTRACT; ROSIGLITAZONE; SALVIA MILTIORRHIZA EXTRACT; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL; TRIGONELLA FOENUM GRAECUM EXTRACT; UNINDEXED DRUG;

CELL ACTIVITY; CHOLELITHIASIS; CLINICAL PRACTICE; DISEASE ASSOCIATION; DRUG DESIGN; DRUG RESEARCH; DRUG TARGETING; DYSLIPIDEMIA; GENE EXPRESSION; HEART INFARCTION; HERBAL MEDICINE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; MUSCLE WEAKNESS; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; WEIGHT GAIN;

ANIMALS; DRUG DISCOVERY; DRUG TOXICITY; HUMANS; LIGANDS; METABOLIC SYNDROME X; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 67651154149     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.03.020     Document Type: Review

References (135)

1. World health statistics (WHO) 2006; 1-80 (http://www.who.int/).
2. Day C. Metabolic syndrome, or what you will: definitions and epidemiology. Diab Vasc Dis Res 4 1 (2007) 32-38
3. Demers A., Rodrigue-Way A., and Tremblay A. Hexarelin signaling to PPARgamma in metabolic diseases. PPAR Res 2008 (2008) 364784
4. Bays H., and Stein E.A. Pharmacotherapy for dyslipidaemia-current therapies and future agents. Exp Opin Pharmacother 4 11 (2003) 1901-1938
5. Cho M.C., Lee K., Paik S.G., and Yoon D.Y. Peroxisome proliferators-activated receptor (PPAR) modulators and metabolic disorders. PPAR Res 2008 (2008) 679137
6. Shay N.F., and Banz W.J. Regulation of gene transcription by botanicals: novel regulatory mechanisms. Annu Rev Nutr 25 (2005) 297-315
7. Yu K., Bayona W., Kallen C.B., Harding H.P., Ravera C.P., McMahon G., et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 270 41 (1995) 23975-23983
8. Bensinger S.J., and Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454 7203 (2008) 470-477
9. Wang Y.D., Chen W.D., Moore D.D., and Huang W. FXR: a metabolic regulator and cell protector. Cell Res 18 11 (2008) 1087-1095
10. Huang T.H., Kota B.P., Razmovski V., and Roufogalis B.D. Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome. Basic Clin Pharmacol Toxicol 96 (2005) 3-14
11. Han K.L., Choi J.S., Lee J.Y., Song J., Joe M.K., Jung M.H., et al. Therapeutic potential of peroxisome proliferators-activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes. Diabetes 57 3 (2008) 737-745
12. Davis S.N. Contemporary strategies for managing cardiometabolic risk factors. J Manag Care Pharm 12 1 Suppl (2006) S4-S9
13. Isomaa B., Almgren P., Tuomi T., Forsén B., Lahti K., Nissén M., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 4 (2001) 683-689
14. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 9468 (2005) 1415-1428
15. Lottenberg S.A., Glezer A., and Turatti L.A. Metabolic syndrome: identifying the risk factors. J Pediatr (Rio J) 83 5 Suppl (2007) S204-S208
16. Zderic T.W., Davidson C.J., Schenk S., Byerley L.O., and Coyle E.F. High-fat diet elevates resting intramuscular triglyceride concentration and whole body lipolysis during exercise. Am J Physiol Endocrinol Metab 286 2 (2004) E217-E225
17. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 3 (2002) 356-359
18. Daskalopoulou S.S., Mikhailidis D.P., and Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology 55 6 (2004) 589-612
19. Lien L.F., and Guyton J.R. Metabolic syndrome. Dermatol Ther 21 5 (2008) 362-375
20. Wajchenberg B.L., and Subcutaneous. visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21 6 (2000) 697-738
21. Després J.P., Cartier A., Côté M., and Arsenault B.J. The concept of cardiometabolic risk: bridging the fields of diabetology and cardiology. Ann Med 40 7 (2008) 514-523
22. Dagenais G.R., Yi Q., Mann J.F., Bosch J., Pogue J., and Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 149 1 (2005) 54-60
23. Willett W.C., Dietz W.H., and Colditz G.A. Guidelines for healthy weight. N Engl J Med 341 6 (1999) 427-434
24. Chinetti G., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49 10 (2000) 497-505
25. Neve B.P., Fruchart J.C., and Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 60 8 (2000) 1245-1250
26. Fan Y., Wang Y., Tang Z., Zhang H., Qin X., Zhu Y., et al. Suppression of pro-inflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 28 2 (2008) 315-321
27. Lee H., Shi W., Tontonoz P., Wang S., Subbanagounder G., Hedrick C.C., et al. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res 87 6 (2000) 516-521
28. Willson T.M., Brown P.J., Sternbach D.D., and Henke B.R. The PPARs: from orphan receptors to drug discovery. J Med Chem 43 4 (2000) 527-550
29. Yu S., Rao S., and Reddy J.K. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med 3 September (6) (2003) 561-572
30. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 18 5 (2002) 269-276
31. Barbier O., Torra I.P., Duguay Y., Blanquart C., Fruchart J.C., Glineur C., et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22 5 (2002) 717-726
32. Knight B.L., Patel D.D., Humphreys S.M., Wiggins D., and Gibbons G.F. Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice. J Lipid Res 44 11 (2003) 2049-2058
33. Nakamachi T., Nomiyama T., Gizard F., Heywood E.B., Jones K.L., Zhao Y., et al. PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes. Diabetes 56 6 (2007) 1662-1670
34. Staels B., Maes M., and Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 5 9 (2008) 542-553
35. Luquet S., Gaudel C., Holst D., Lopez-Soriano J., Jehl-Pietri C., Fredenrich A., et al. Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes. Biochim Biophys Acta 1740 2 (2005) 313-317
36. Barish G.D., Narkar V.A., and Evans R.M. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 116 3 (2006) 590-597
37. Oliver Jr. W.R., Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 98 9 (2001) 5306-5311
38. Tanaka T., Yamamoto J., Iwasaki S., Asaba H., Hamura H., Ikeda Y., et al. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A 100 26 (2003) 15924-15929
39. Welch J.S., Ricote M., Akiyama T.E., Gonzalez F.J., and Glass C.K. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci U S A 100 11 (2003) 6712-6717
40. Akiyama T.E., Lambert G., Nicol C.J., Matsusue K., Peters J.M., Brewer Jr. H.B., et al. Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet. J Biol Chem 279 20 (2004) 20874-20881
41. Tan N.S., Michalik L., Noy N., Yasmin R., Pacot C., Heim M., et al. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 15 24 (2001) 3263-3277
42. Jehl-Pietri C., Bastie C., Gillot I., Luquet S., and Grimaldi P.A. Peroxisome-proliferator-activated receptor delta mediates the effects of long-chain fatty acids on post-confluent cell proliferation. Biochem J 350 Pt 1 (2000) 93-98
43. Risérus U., Sprecher D., Johnson T., Olson E., Hirschberg S., Liu A., et al. Activation of peroxisome proliferator-activated receptor (PPAR) delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 57 2 (2008) 332-339
44. Dubois M., Pattou F., Kerr-Conte J., Gmyr V., Vandewalle B., Desreumaux P., et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 43 9 (2000) 1165-1169
45. Tontonoz P., Hu E., Graves R.A., Budavari A.I., and Spiegelman B.M. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8 10 (1994) 1224-1234
46. Pakala R., Kuchulakanti P., Rha S.W., Cheneau E., Baffour R., and Waksman R. Peroxisome proliferator-activated receptor gamma: its role in metabolic syndrome. Cardiovasc Radiat Med 5 2 (2004) 97-103
47. Rangwala S.M., and Lazar M.A. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 25 6 (2004) 331-336
48. Fernandez A.Z. Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis. PPAR Res 2008 (2008) 285842
49. Murphy G.J., and Holder J.C. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 21 12 (2000) 469-474
50. Rubenstrunk A., Hanf R., Hum D.W., Fruchart J.C., and Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 1771 8 (2007) 1065-1081
51. Graham D.J., Staffa J.A., Shatin D., Andrade S.E., Schech S.D., La Grenade L., et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292 21 (2004) 2585-2590
52. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 24 (2007) 2457-2471
53. Home P.D., Pocock S.J., Beck-Nielsen H., Gomis R., Hanefeld M., Jones N.P., et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 357 1 (2007) 28-38
54. Susman J. Rosiglitazone: failure of oversight or demons imagined?. J Fam Pract 56 9 (2007) 696, 703
55. Rieusset J., Touri F., Michalik L., Escher P., Desvergne B., Niesor E., et al. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 16 11 (2002) 2628-2644
56. Zhang F., Lavan B.E., and Gregoire F.M. Selective modulators of ppar-gamma activity: molecular aspects related to obesity and side-effects. PPAR Res 2007 (2007) 32696
57. Allen T., Zhang F., Moodie S.A., Clemens L.E., Smith A., Gregoire F., et al. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity. Diabetes 55 9 (2006) 2523-2533
58. Burgermeister E., Schnoebelen A., Flament A., Benz J., Stihle M., Gsell B., et al. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol Endocrinol 20 4 (2006) 809-830
59. Feldman P.L., Lambert M.H., and Henke B.R. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?. Curr Top Med Chem 8 9 (2008) 728-749
60. Nissen S.E., Wolski K., and Topol E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294 20 (2005) 2581-2586
61. Fiévet C., Fruchart J.C., and Staels B. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 6 6 (2006) 606-614
62. Tenenbaum A., Motro M., and Fisman E.Z. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 4 (2005) 14
63. Ramachandran U., Kumar R., and Mittal A. Fine tuning of PPAR ligands for type 2 diabetes and metabolic syndrome. Mini Rev Med Chem 6 5 (2006) 563-573
64. Balakumar P., Rose M., Ganti S.S., Krishan P., and Singh M. PPAR dual agonists: are they opening Pandora's Box?. Pharmacol Res 56 2 (2007) 91-98
65. Carpentier Y.A., Portois L., and Malaisse W.J. n-3 fatty acids and the metabolic syndrome. Am J Clin Nutr 83 6 Suppl (2006) 1499S-1504S
66. Nagao K., and Yanagita T. Bioactive lipids in metabolic syndrome. Prog Lipid Res 47 2 (2008) 127-146
67. Bordoni A., Di Nunzio M., Danesi F., and Biagi P.L. Polyunsaturated fatty acids: from diet to binding to ppars and other nuclear receptors. Genes Nutr 1 2 (2006) 95-106
68. Saklani A., and Kutty S.K. Plant-derived compounds in clinical trials. Drug Discov Today 13 3-4 (2008) 161-171
69. Itokawa H., Morris-Natschke S.L., Akiyama T., and Lee K.H. Plant-derived natural product research aimed at new drug discovery. Nat Med (Tokyo) 62 (2008) 263-280
70. Choi H., Eo H., Park K., Jin M., Park E.J., Kim S.H., et al. A water-soluble extract from Cucurbita moschata shows anti-obesity effects by controlling lipid metabolism in a high fat diet-induced obesity mouse model. Biochem Biophys Res Commun 359 (2007) 419-425
71. Lee J., Chae K., Ha J., Park B.Y., Lee H.S., Jeong S., et al. Regulation of obesity and lipid disorders by herbal extracts from Morus alba, Melissa officinalis, and Artemisia capillaries in high-fat diet-induced obese mice. J Ethnopharmacol 115 (2008) 263-270
72. Kwon H.J., Hyun S.H., and Choung S.Y. Traditional Chinese Medicine improves dysfunction of peroxisome proliferator-activated receptor alpha and microsomal triglyceride transfer protein on abnormalities in lipid metabolism in ethanol-fed rats. Biofactors 23 3 (2005) 163-176
73. Monden T., Hosoya T., Nakajima Y., Kishi M., Satoh T., Hashimoto K., et al. Herbal medicine, Hachimi-jio-gan, and its component cinnamomi cortex activate the peroxisome proliferator-activated receptor alpha in renal cells. Endocr J 55 3 (2008) 529-533
74. Huang T.H., Peng G., Li G.Q., Yamahara J., Roufogalis B.D., and Li Y. Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: activation of PPAR-alpha. Toxicol Appl Pharmacol 210 3 (2006) 225-235
75. Huang T.H., Yang Q., Harada M., Uberai J., Radford J., Li G.Q., et al. Salacia oblonga root improves cardiac lipid metabolism in Zucker diabetic fatty rats: modulation of cardiac PPAR-alpha-mediated transcription of fatty acid metabolic genes. Toxicol Appl Pharmacol 210 1-2 (2006) 78-85
76. Huang T.H., Li Y., Razmovski-Naumovski V., Tran V.H., Li G.Q., Duke C.C., et al. Gypenoside XLIX isolated from Gynostemma pentaphyllum inhibits nuclear factor-kappaB activation via a PPAR-alpha-dependent pathway. J Biomed Sci 13 4 (2006) 535-548
77. Huang T.H., Tran V.H., Roufogalis B.D., and Li Y. Gypenoside XLIX, a naturally occurring PPAR-alpha activator, inhibits cytokine-induced vascular cell adhesion molecule-1 expression and activity in human endothelial cells. Eur J Pharmacol 565 (2007) 158-165
78. Huang T.H., Tran V.H., Roufogalis B.D., and Li Y. Gypenoside XLIX, a naturally occurring gynosaponin, PPAR-alpha dependently inhibits LPS-induced tissue factor expression and activity in human THP-1 monocytic cells. Toxicol Appl Pharmacol 218 1 (2007) 30-36
79. Fu J., Gaetani S., Oveisi F., Lo Verme J., Serrano A., Rodríguez De Fonseca F., et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425 6953 (2003) 90-93
80. O'Sullivan S.E. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152 5 (2007) 576-582
81. Isa Y., Miyakawa Y., Yanagisawa M., Goto T., Kang M.S., Kawada T., et al. 6-Shogaol and 6-gingerol, the pungent of ginger, inhibit TNF-a mediated downregulation of adiponectin expression via different mechanisms in 3T3-L1 adipocytes. Biochem Biophys Res Commun 373 (2008) 429-434
82. Saito T., Abe D., and Sekiya K. Sakuranetin induces adipogenesis of 3T3-L1 cells through enhanced expression of PPARγ2. Biochem Biophys Res Commun 372 (2008) 835-839
83. Han K.L., Jung M.H., Sohn T.H., and Hwang J.K. Ginsenoside 20(S)-Protopanaxatriol (PPT) activates peroxisome proliferator-activated receptor γ (PPARγ) in 3T3-L1 adipocytes. Biol Pharm Bull 29 1 (2006) 110-113
84. Shang W., Yang Y., Jiang B., Jin H., Zhou L., Liu S., et al. Ginsenoside Rb1 promotes adipogenesis in 3T3-L1 cells by enhancing PPARγ2 and C/EBPα gene expression. Life Sci 80 (2007) 110-113
85. Hwang J.T., Kim S.H., Lee M.S., Kim S.H., Yang H.J., Kim M.J., et al. Anti-obesity effects of ginsenoside Rh2 are associated with the activation of AMPK signalling pathway in 3T3-L1 adipocyte. Biochem Biophys Res Commun 364 (2007) 1002-1008
86. Hwang J.T., Lee M.S., Kim H.J., Sung M.J., Kim H.Y., Kim M.S., et al. Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR-gamma signal pathways. Phytother Res 23 2 (2009) 262-266
87. Gong Z., Huang C., Sheng X., Zhang Y., Li Q., Wang M.W., et al. The role of Tanshinone IIA in the treatment of obesity through PPARγ antagonism. Endocrinology 150 1 (2009) 104-113
88. Fang X.K., Gao J., and Zhu D.N. Kaempferol and quercetin isolated from Euonymus alatus improve glucose uptake of 3T3-L1 cells without adipogenesis activity. Life Sci 82 11-12 (2008) 615-622
89. Yadav H., Jain S., Prasad G.B., and Yadav M. Preventive effect of diabegon, a polyherbal preparation, during progression of diabetes induced by high-fructose feeding in rats. J Pharmacol Sci 105 1 (2007) 12-21
90. Shih C.C., Lin C.H., and Lin W.L. Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet. Diab Res Clin Pract 81 (2008) 134-143
91. Cornick C.L., Strongitharm B.H., Sassano G., Rawlins C., Mayes A.E., Joseph A.N., et al. Identification of a novel agonist of peroxisome proliferator-activated receptors α and γ that may contribute to the anti-diabetic activity of guggulipid in Lepob/Lepob mice. J Nutr Biochem October (14) (2008) [Epub ahead of print]
92. Park S.H., Ko S.K., and Chung S.H. Euonymus alatus prevents the hyperglycemia and hyperlipidemia induced by high-fat diet in ICR mice. J Ethnopharmacol 102 3 (2005) 326-335
93. Huang T.H., Yang Q., Harada M., Li G.Q., Yamahara J., Roufogalis B.D., et al. Pomegranate flower extract diminishes cardiac fibrosis in Zucker diabetic fatty rats: modulation of cardiac endothelin-1 and nuclear factor-kappaB pathways. J Cardiovasc Pharmacol 46 6 (2005) 856-862
94. Jaradat M.S., Noonan D.J., Wu B., Avery M.A., and Feller D.R. Pseudolaric acid analogs as a new class of peroxisome proliferator-activated receptor agonists. Planta Med 68 8 (2002) 667-671
95. Huang T.H., Razmovski-Naumovski V., Salam N.K., Duke R.K., Tran V.H., Duke C.C., et al. A novel LXR-alpha activator identified from the natural product Gynostemma pentaphyllum. Biochem Pharmacol 70 9 (2005) 1298-1308
96. Herath K., Jayasuriya H., Ondeyka J.G., Guan Z., Borris R.P., Stijfhoorn E., et al. Guttiferone I, a new prenylated benzophenone from Garcinia humilis as a liver X receptor ligand. J Nat Prod 68 4 (2005) 617-619
97. Kim K.H., Choi S.H., Lee T.S., Oh W.K., Kim D.S., and Kim J.B. Selective LXRalpha inhibitory effects observed in plant extracts of MEH184 (Parthenocissua tricuspidata) and MEH185 (Euscaphis japonica). Biochem Biophys Res Commun 349 2 (2006) 513-518
98. Chiang J.Y. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol 40 3 (2004) 539-551
99. Ulbricht C., Basch E., Szapary P., Hammerness P., Axentsev S., Boon H., et al. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med 13 4 (2005) 279-290
100. Suzuki T., Nishimaki-Mogami T., Kawai H., Kobayashi T., Shinozaki Y., Sato Y., et al. Screening of novel nuclear receptor agonists by a convenient reporter gene assay system using green fluorescent protein derivatives. Phytomedicine 13 6 (2006) 401-411
101. Li Y., Huang T.H., and Yamahara J. Salacia root, a unique Ayurvedic medicine, meets multiple targets in diabetes and obesity. Life Sci 82 21-22 (2008) 1045-1049
102. Miura T., Iwamoto N., Kato M., Ichiki H., Kubo M., Komatsu Y., et al. The suppressive effect of mangiferin with exercise on blood lipids in type 2 diabetes. Biol Pharm Bull 24 9 (2001) 1091-1092
103. Huang T.H., He L., Qin Q., Yang Q., Peng G., Harada M., et al. Salacia oblonga root decreases cardiac hypertrophy in Zucker diabetic fatty rats: inhibition of cardiac expression of angiotensin II type 1 receptor. Diabetes Obes Metab 10 7 (2008) 574-585
104. Yin F., Hu L., Lou F., and Pan R. Dammarane-type glycosides from Gynostemma pentaphyllum. J Nat Prod 67 6 (2004) 942-952
105. Marx N., Mackman N., Schönbeck U., Yilmaz N., Hombach V., Libby P., et al. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 103 2 (2001) 213-219
106. Hope S.A., and Meredith I.T. Cellular adhesion molecules and cardiovascular disease. Part II. Their association with conventional and emerging risk factors, acute coronary events and cardiovascular risk prediction. Int Med J 33 9-10 (2003) 450-462
107. Marx N., Sukhova G.K., Collins T., Libby P., and Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99 24 (1999) 3125-3131
108. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 94 9 (1997) 4318-4323
109. Sun Y., Alexander S.P., Kendall D.A., and Bennett A.J. Cannabinoids and PPARalpha signalling. Biochem Soc Trans 34 Pt 6 (2006) 1095-1097
110. Yan Z.C., Liu D.Y., Zhang L.L., Shen C.Y., Ma Q.L., Cao T.B., et al. Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochem Biophys Res Commun 354 2 (2007) 427-433
111. Attele A.S., Wu J.A., and Yuan C.S. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 58 11 (1999) 1685-1693
112. Lee J., Jung E., Lee J., Kim S., Huh S., Kim Y., et al. Isorhamnetin represses adipogenesis in 3T3-L1 cells. Obesity (Silver Spring) 17 2 (2009) 226-232
113. Ji X., Tan B.K., Zhu Y.C., Linz W., and Zhu Y.Z. Comparison of cardioprotective effects using ramipril and DanShen for the treatment of acute myocardial infarction in rats. Life Sci 73 11 (2003) 1413-1426
114. Hur J.M., Shim J.S., Jung H.J., and Kwon H.J. Cryptotanshinone but not tanshinone IIA inhibits angiogenesis in vitro. Exp Mol Med 37 2 (2005) 133-137
115. Peng L., Li Z.Y., and Bao Y.G. Clinical study of compound Ramulus euonymi decoction in improving insulin resistance and hemorheological parameters of hypertension patients. J Guangzhou Univ Tradit Chin Med 24 1 (2007) 14-16
116. Li Y., Qi Y., Huang T.H., Yamahara J., and Roufogalis B.D. Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties. Diabetes Obes Metab 10 1 (2008) 10-17
117. Huang T.H., Peng G., Kota B.P., Li G.Q., Yamahara J., Roufogalis B.D., et al. Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: role of lowering circulating lipids. Br J Pharmacol 145 6 (2005) 767-774
118. Lee H.K., Nam G.W., Kim S.H., and Lee S.H. Phytocomponents of triterpenoids, oleanolic acid and ursolic acid, regulated differently the processing of epidermal keratinocytes via PPAR-alpha pathway. Exp Dermatol 15 1 (2006) 66-73
119. Huang T.H., Peng G., Kota B.P., Li G.Q., Yamahara J., Roufogalis B.D., et al. Anti-diabetic action of Punica granatum flower extract: activation of PPAR-gamma and identification of an active component. Toxicol Appl Pharmacol 207 2 (2005) 160-169
120. Appeldoorn C.C., Bonnefoy A., Lutters B.C., Daenens K., van Berkel T.J., Hoylaerts M.F., et al. Gallic acid antagonizes P-selectin-mediated platelet-leukocyte interactions: implications for the French paradox. Circulation 111 1 (2005) 106-112
121. Gill S., Chow R., and Brown A.J. Sterol regulators of cholesterol homeostasis and beyond: the oxysterol hypothesis revisited and revised. Prog Lipid Res 47 6 (2008) 391-404
122. Lehmann J.M., Kliewer S.A., Moore L.B., Smith-Oliver T.A., Oliver B.B., Su J.L., et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 272 6 (1997) 3137-3140
123. Bramlett K.S., Houck K.A., Borchert K.M., Dowless M.S., Kulanthaivel P., Zhang Y., et al. A natural product ligand of the oxysterol receptor, liver X receptor. J Pharmacol Exp Ther 307 1 (2003) 291-296
124. Kase E.T., Thoresen G.H., Westerlund S., Højlund K., Rustan A.C., and Gaster M. Liver X receptor antagonist reduces lipid formation and increases glucose metabolism in myotubes from lean, obese and type 2 diabetic individuals. Diabetologia 50 10 (2007) 2171-2180
125. Kase E.T., Andersen B., Nebb H.I., Rustan A.C., and Thoresen G.H. 22-Hydroxycholesterols regulate lipid metabolism differently than T0901317 in human myotubes. Biochim Biophys Acta 1761 12 (2006) 1515-1522
126. Cai S.Y., Xiong L., Wray C.G., Ballatori N., and Boyer J.L. The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution. Am J Physiol Regul Integr Comp Physiol 293 3 (2007) R1400-R1409
127. Urizar N.L., and Moore D.D. GUGULIPID: a natural cholesterol-lowering agent. Annu Rev Nutr 23 (2003) 303-313
128. Urizar N.L., Dowhan D.H., and Moore D.D. The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J Biol Chem 275 50 (2000) 39313-39317
129. Nam S.J., Ko H., Ju M.K., Hwang H., Chin J., Ham J., et al. Scalarane sesterterpenes from a marine sponge of the genus Spongia and their FXR antagonistic activity. J Nat Prod 70 11 (2007) 1691-1695
130. Urizar N.L., Liverman A.B., Dodds D.T., Silva F.V., Ordentlich P., Yan Y., et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296 5573 (2002) 1703-1706
131. Maloney P.R., Parks D.J., Haffner C.D., Fivush A.M., Chandra G., Plunket K.D., et al. Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 43 16 (2000) 2971-2974
132. Hirata Y., and Nakanishi K. Grifolin, an antibiotic from a basidiomycete. J Biol Chem 184 (1949) 135-143
133. Morimoto H., Kawamatsu Y., and Sugihara H. Stereo-structure of toxin from the fruit of Ginkgo biloba L. Chem Pharm Bull (Tokyo) 16 11 (1968) 2282-2286
134. Forman B.M., Goode E., Chen J., Oro A.E., Bradley D.J., Perlmann T., et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81 5 (1995) 687-693
135. Suzuki T., Tamehiro N., Sato Y., Kobayashi T., Ishii-Watabe A., Shinozaki Y., et al. The novel compounds that activate farnesoid X receptor: the diversity of their effects on gene expression. J Pharmacol Sci 107 3 (2008) 285-294